Epstein Secrets

nterfere with the 2020 presidential election, calling accusations of hacking unfounded." US Officials Remain More Concerned About Russia Than Iran. The New Ynrk Times (10/22, Barnes, Perlroth, Sanger, 18.61M) reports that "while senior Trump administration officials said this week that Iran has been actively inte

er corporate criminal bribery law." The AP (10/22, Balsamo, Sweet) reports, "Goldman Sachs Malaysia entered the plea in federal court in Brooklyn." The New York Timing (10/22, Goldstein, Flitter, 18.61M) says Goldman "admitted its Malaysian subsidiary 'knowingly and willingly' conspired to violate the Foreign Corr

Efficacy Standards For Vaccine. The Washington Post (10/22, McGinley, Johnson, 14.2M) reports that vaccine experts on Thursday "rigorously debated the Food and Drug Administration's planned standards for clearing a coronavirus vaccine quickly for broad use, discussing what level of evidence would be sufficient to establish safe

be a greater force for Japanese globalization than could have been expected. NYTimes: Shinzo Abe's Successor Has A Legacy Of Change To Build On. A New York Times (9/2, 18.61M) editorial argues that Japan's next prime minister "will lack Mr. Abe's greatest asset - the political power he amassed by simply stayi

or Efficacy Or Safety Of Convalescent Plasma. In an op-ed for the New York Times (9/2, 18.61M), Daniela J. Lamas, a critical care doctor, questions the Food and Drug Administration's "emergency use authorization for convalescent plasma despite inadequate evidence." Lamas writes that possible treatments must undergo clinical tria

be a greater force for Japanese globalization than could have been expected. NYTimes: Shinzo Abe's Successor Has A Legacy Of Change To Build On. A New York Times (9/2, 18.61M) editorial argues that Japan's next prime minister "will lack Mr. Abe's greatest asset - the political power he amassed by simply stayi

or Efficacy Or Safety Of Convalescent Plasma. In an op-ed for the New York Times (9/2, 18.61M), Daniela J. Lamas, a critical care doctor, questions the Food and Drug Administration's "emergency use authorization for convalescent plasma despite inadequate evidence." Lamas writes that possible treatments must undergo clinical tria